CureVac N.V. CVAC
At closeJan 6, 2026, 4:00 PM EST
After hours · Jan 6, 4:00 PM ET
- YTD
- +3.10%
- 1 year
- +28.73%
- Market cap
- 1.05B
- Profit margin
- 385.83%
- EPS (ttm)
- 0.72
- YTD return
- +3.10%
- 1-year return
- +28.73%
- Volume
- 728.78K
- Avg volume
- 1.76M
- Open
- 4.57
- Previous close
- 4.66
- Day's range
- 4.57 – 4.66
- 52-week range
- 4.00 – 5.55
- Beta
- 1.84
YTD -0.01 (-0.21%)
Key statistics
- Enterprise value
- 556.32M
- PEG ratio
- 0.31
- Price / sales
- 16.93
- Price / book
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 29.32%
Analyst view
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2025 | Nov 24, 2025 | -0.17 | -0.10 | +0.07 | +41.18% |
| Aug 15, 2025 | Jun 30, 2025 | -0.18 | -0.30 | -0.12 | -66.67% |
| May 20, 2025 | Mar 31, 2025 | -0.16 | -0.24 | -0.08 | -50.00% |
| Apr 10, 2025 | Dec 31, 2024 | -0.21998 | -0.15 | +0.07 | +31.81% |
| Nov 12, 2024 | Sep 30, 2024 | 0.67 | 1.65 | +0.98 | +146.27% |
| Aug 15, 2024 | Jun 30, 2024 | -0.28 | -0.34 | -0.06 | -21.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 26, 2025 | UBS | down | Buy | Neutral |
| Jun 13, 2025 | Jefferies | down | Buy | Hold |
| May 28, 2025 | JMP Securities | reit | Market Outperform | Market Outperform |
| Apr 30, 2025 | UBS | main | Buy | Buy |
| Feb 14, 2025 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 16, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
About CureVac N.V.
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- DE
- Employees
- 825
- Website
- curevac.com
News
Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
Why Clearwater Analytics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket 
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher 
5 Stocks To Ride The German Market Rally 
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday 
Earnings Scheduled For November 12, 2024 
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday - Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Your note
Sign in to keep a note on CVAC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Glazer Capital LLC | 2.03% | 4,546,634 | 18.78M | Sep 29, 2025 |
| Alpine Associates Management Inc. | 1.02% | 2,295,422 | 9.48M | Sep 29, 2025 |
| Qube Research & Technologies Ltd | 0.76% | 1,712,737 | 7.07M | Sep 29, 2025 |
| Blackrock Inc. | 0.45% | 1,016,297 | 4.20M | Sep 29, 2025 |
| AQR Arbitrage LLC | 0.44% | 991,688 | 4.10M | Sep 29, 2025 |
| Water Island Capital, LLC | 0.34% | 762,138 | 3.15M | Sep 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core MSCI EAFE ETF | 0.31% | 692,389 | 2.86M | Sep 29, 2025 |
| ARBITRAGE FUNDS-ARBITRAGE FUND | 0.29% | 655,000 | 2.71M | Aug 30, 2025 |
| iShares Trust-iShares Biotechnology ETF | 0.25% | 563,088 | 2.33M | Sep 29, 2025 |
| AQR Funds-AQR Diversified Arbitrage Fund | 0.15% | 329,827 | 1.36M | Sep 29, 2025 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 0.14% | 323,052 | 1.33M | Sep 29, 2025 |
| AltShares Trust-AltShares Merger Arbitrage ETF | 0.12% | 262,293 | 1.08M | Aug 30, 2025 |